Immunological effects following administration of interferon-α in patients with chronic hepatitis C virus (cHCV) infection.

Immunopharmacology and Immunotoxicology

Volumn 18, Issue 3, 1996, Pages 355-374

  Jirillo, Emilio ^a,b   Greco, Beatrice ^b   Caradonna, Luigi ^b   Satalino, Rosa ^b   Amati, Luigi ^b   Cozzolongo, Raffaele ^b   Cuppone, Renato ^b   Manghisi, Onofrio G ^b  

^a UNIVERSITY OF BARI   (Italy)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD14 ANTIGEN; CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEPATITIS C; HUMAN; LYMPHOCYTE SUBPOPULATION; MALE; MONOCYTE; NEUTROPHIL; PHAGOCYTOSIS; PRIORITY JOURNAL;

HEPATITIS C VIRUS; SALMONELLA TYPHI;

EID: 0029843760     PISSN: 08923973     EISSN: None     Source Type: Journal    
DOI: 10.3109/08923979609052741     Document Type: Article

References (34)

1. Alter, M.J., Margolis, H.S., Krawczynski, K. et al., The natural history of community acquired hepatitis C in the United States, New Engl. J. Med., 327:1899, 1992.
2. Jirillo, E., Greco, B., Caradonna, L. et al., Evaluation of cellular responses and soluble mediators in patients with chronic hepatitis C virus (cHCV) infection, Immunopharm. Immunot. 17:347,1995.
3. Tilg, H., Wilmer, A., Vogel, W. et al., Serum levels of cytokines in chronic liver diseases, Gastroenterology, 103:264, 1992.
4. Smith, C.A., Farrah, T., Goodwin, R.G., The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death, Cell, 76:959,1994.
5. Muller, C., Knoflach, P., Zielinski, C.C., Soluble interleukin 2 receptor in acute viral hepatitis and chronic liver disease, Hepatology, 10:928, 1989.
6. Adams, D.H., Mainolfi, E., Burra, P. et al., Detection of circulating intercellular adhesion molecule-1 in chronic liver diseases, Hepatotogy, 16:810, 1992.
7. Zohrens, G., Armbrust, T., Pirzer, U. et al., intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: relationship to disease activity and cirrhosis, Hepatology, 18:798, 1993.
8. Symons, J.A., Wood, N.C., Di Giovine, F.S. et al., Soluble IL-2 receptor in rheumatoid arthritis: correlation with disease activity, IL-1 and IL-2 inhibition, J. Immunol., 141:2612, 1988.
9. Barton, D.P.J., Blanchard, O.K., Michelini-Norris, B. et al., Serum soluble interleukin-2 receptor a. levels in patients with gynecological cancers: early effect of surgery, Am. J. Reprod. Immunol., 30:202, 1993.
10. Van Deventer, S.J.H., Ten Cate, J.W., Tytgat, G.N.J., Intestinal endotoxinemia:clinical significance, Gastroenterology, 94:825, 1988.
11. Danner, R.L., Elin, R.J., Hosseini, J.M. et al., Endotoxaemia in human septic shock, Chest, 99:169, 1991.
12. Oesterreicher, C., Pfeffel, F., Petermann, D. et al., Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease, J. Hepatol., 23:396, 1995.
13. Steinmann. G.G., Rosenkamer, F., Leitz G., Clinical experiences with interferon-α and interferon-γ, Int. Rev. Ex. Pathol., 34B:193, 1993.
14. Dianzani, F., Interferon toxicity. A mechanistic view, Trends Ex. Clin. Med., 4:397, 1995.
15. Boyum, A., Isolation of mononuclear cells and granulocytes from human blood, Scand. J. Clin. Lab. Inv., 21 (suppl. 97):77, 1968.
16. Mandell, L., Hook, W.E., Leukocyte function in chronic granulomatous diseases of childhood, Am. J. Med., 47:473, 1969.
17. Antonaci, S., Tortorella, C., De Simone, C. et al., Role of bacterial lipopolysaccharides in the development of natural antibacterial activity mediated by human peripheral blood T lymphocytes, Int. Rev. Immunol., 6:237, 1990.
18. Wejstal, R., Immune-mediated liver damage in chronic hepatitis C, Scand. J. Gastroenterol., 30:609, 1995.
19. Lindsay, K.L., Davis, G.L., Bodenheimer, H.C. et al., Predictors of relapse and response to re-treatment in patients with an initial response to recombinant alpha interferon (r IFN) therapy for chronic hepatitis C, Hepatology, 12:847, 1990.
20. Cimino, L., Nardone, G., Citarella, C. et al., Treatment of chronic hepatitis C with recombinant interferon alpha, Ital. J. Gastroenterol., 23:399, 1991.
21. Di Bisceglie, A.M., Hoofnagle, J.H., Therapy of chronic hepatitis C with alpha interferon:the answer? or more questions?, Hepatology, 13:601, 1991.
22. Weiland, O., Interferon therapy in chronic hepatitis C virus infection, FEMS. Microbiol. Rev. 14:279, 1994.
23. Cuthbert, U.A., Hepatitis C : progress and problems, Clin. Microbiol. Rev., 7:505, 1994.
24. Cerny, A., Chisari, F.V., Immunological aspects of HCV infection, Intervirology, 37:119,1994.
25. Gonzalez-Peralta, R.P., Davis, G.L., Lav, J.Y.N., Pathogenetic mechanism of hepatocellular damage in chronic hepatitis C virus infection, J. Hepatol., 21:255,1994.
26. Mauss, S., Heintges, T., Adams, O. Et al., Treatment of chronic hepatitis C with interferon-α in patients infected with the human immunodeficiency virus. Hepato-Gastroenterol., 42:528, 1995.
27. Li, X., Jeffers, L.J., Reddy, K.R. et al., Immunophenotyping of lymphocytes in liver tissue of patients with chronic liver diseases by flow cytometry, Hepatology, 14:121, 1991.
28. Scully, L.J., Brown, D., Lloyd, C. et al., Immunologicai studies before and during interferon therapy in chronic HBV infection:identification of factors predicting response, Hepatology, 12:1111, 1990.
29. Puppo, F., Picciotto, A., Brenci, S. et al., Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?, J. Clin, Immunol., 4:179, 1995.
30. Matsunaga, T., Kojima, J., Inoue, A. et al., Prediction of sustained response to interferon alpha therapy with serum soluble interleukin 2 receptor levels in patients with chronic hepatitis C, Int. Hepatol. Communic., 3:173, 1995.
31. Saito, H., Atsukawa, K., Morizane, T. et al., Correlation between response to Interferon therapy and in vitro antibody production in patients with chronic hepatitis C, Clin, Immunot, Immunop., 1:209, 1995.
32. Guadagnino, V., Caroleo, B., Izzi, A. et al., T-lymphocyte subpopulations as factors predicting clinical response to interferon in hepatitis C virus-related chronic active hepatitis, Infection, 3:189, 1995.
33. Veno, T., Inuzuka, S., Sata, M. Et al., Serum hyaluronate predictis response to interferon-α therapy in patients with chronic hepatitis C, Hepato-Gastroenterol., 42:523, 1995.
34. Ishibashi, K., Kashiwagi, T., Ito, A. et al., Predictive factors for efficacy of interferon therapy in chronic hepatitis type C, Hepato-Gastroenterol., 42:535, 1995.